The production of cytokines in monocytes/macrophages is regulated by several different cytokines that have activating or inhibitory effects. Interleukin (IL)-10, IL-4, IL-13, and transforming growth factor (TGF)-~ are usually considered to be the most important macrophage-deactivating factors, with inhibitory effects on cytokine production. Unlike IL-IO and TGF-/3, which appear to act as downmodulators of many phagocytic cell functions, the mode of action of IL-4 and IL-13 is more complex. Addition of IL-4 and IL-13 to peripheral blood mononuclear cell (PBMC) cultures inhibited production of II.-12, tumor necrosis factor (TNF)-o~, IL-10, and II:1/~ induced by lipopolysaccharide (LPS) or Staphylococcus aureus added simultaneously with the cytokines. However, pretreatment of PBMC with II.-4 or I1.-13 for >--20 h enhanced the production of I1.-12 and TNF<~ in response to LPS or S. aureus several fold in these cells; this IL-4-induced priming for the two cytokines was inhibited by anti-IL-4 neutralizing antibodies. IL-4 priming also enhanced the accumulation of IL-12 and TNF-ot mR.NA induced by LPS and S. aureus. The enhanced accumulation of transcripts for the 1I.-12 p35 and p40 chains by IL-4 priming was reflected in enhanced secretion of both the IL-12 free p40 chain and the p70 heterodimer. These results suggest an unexpected complexity in the regulatory role of IL-4 and IL-13 in immune responses.
er ability of monocytes/macrophages to act as APCs T cells and as accessory cells for activation of NK cells is mediated in part by the expression of costimulatory molecules, either present at the cell surface (e.g., B7 and cell adhesion molecules) or secreted (e.g., I1.-12, TNF-oz, and ILl). IL-12 is a heterodimeric cytokine produced by several cell types with APC function. IL-12 induces production of IFN-'y from T and NK cells, proliferation of activated T and NK cells, and enhancement of the cytotoxic activity of lymphocytes (1) . Upon infection with bacteria or intracellular parasites, monocytes/macrophages produce IL-12 (2) , which cooperates with TNF-cx and IL-1 as well as with B7 stimulation of the CD28 receptor on T cells in inducing production of IFN-y and lymphocyte proliferation (3) (4) (5) . In cooperation with other costimulatory molecules, IL-12 induces development of Thl cells during an immune response to antigen (6, 7) and is required for optimal proliferation and IFN-3, production by differentiated Thl cells (4, 8) . The light chain (p35) and the heavy chain (p40) of IL-12 are encoded by two distinct genes (9, 10) ; although only the covalently linked p70 heterodimer has known biological activity, the p40 heavy chain is always secreted in large excess over the heterodimer (2, 11) .
The expression or production of costimulatory molecules in monocytes/macrophages is regulated by several cytokines, which have either activating or deactivating effects on various functions of these cells. IFN-3' and GM-CSF are among the stimulatory cytokines, enhancing IL-12 production and other functions of monocytes/macrophages (12, 13) , whereas IL-10, IL-4, and TGF-/~ are usually considered as the most important deactivating factors (14) . Through their effect on accessory cell functions, this latter group of cytokines has an inhibitory effect on many responses of T and NK cells; however, they can also directly affect lymphocyte functions, for example, IL-IO inhibits production of IL-2 by T cells, II.-4 inhibits the response to IL-2, and TGF-B inhibits the response to both IL-2 and IL-12 in T and NK cells (15) (16) (17) , SchartonKerston, T., G. Trinchieri, and P. Scott, unpublished results). I1.-13 is a recently described cytokine that shares one chain (IL-2R3') of its receptor with the Ib4 and IL-2 receptors and mediates similar functions to those mediated by IL-4 on monocytes/macrophages and B cells, but not on T or NK cells (18) (19) (20) .
Unlike IL-10 and TGF-~, which appear to downmodulate many phagocytic cell functions, the mode of action of IL-4 and IL-13 is more complex. On monocytes/macrophages, IL-4 inhibits the expression of IFN-q;-induced genes and the differentiation of these cells, whereas IFN-3, induces their differentiation. II.,4 or IL-13 treatment of monocytes induces the formation of long cytoplasmic protrusions that tightly adhere to substrates, giving them a dendritic appearance (21) . Addition of IL-4 to long-term monocyte cultures grown in the presence of GM-CSF blocks the differentiation to macrophages and the expression of macrophage markers such as CD14 or Fc receptors, while inducing cells that resemble dendritic/Langerhans cells with respect to antigenic phenotype (e.g., expression of CD1) and potent APC functions (22, 23) . Short-term treatment of monocytes with IL-4 or IL-13 enhances the expression of the surface antigens class II MHC, CD11b, CDllc, CD18, and CD23, but downregulates the expression of CD16, CD32, and CD64 (14, (24) (25) (26) (27) (28) (29) (30) . Furthermore, IL-4 and IL-13 inhibit production of IL-lot and -/3, IL-6, IL-8, IL-IO, IL-12 p35 and p40, GM-CSF, M-CSF, G-CSF, IFN-ol, and TNF-ot, but enhance production of the IL-1 receptor antagonist (IL-1RA) 1 by monocytes (14, (30) (31) (32) (33) (34) (35) . However, in one study, IL-4 was shown to induce production of G-CSF and M-CSF from human monocytes (36) . IL-4 was also shown to inhibit cytokine production, including TNF-ot, by mouse peritoneal macrophages, especially if these cells were pretreated with IL-4 before stimulation. However, IL-4 has also been reported to enhance or induce TNF-ct production in LPS-treated or Leishmania-infected peritoneal macrophages (37, 38) . These contrasting results may reflect the use of different cell populations and experimental conditions (39) , but possibly also species differences, as suggested by the observation that pretreatment with IL-4 inhibits the stimulus-dependent respiratory burst in human monocytes but enhances it in murine macrophages (40) .
In this study, we show that pretreatment of PBMC with IL-4 or IL-13 for/>20 h enhances several fold their ability to produce IL-12 and TNF-ot in response to Staphylococcus aureus or LPS. This priming effect was reflected in a similar increase in stimulus-dependent accumulation of cytokine mRNA.
Materials and Methods
Cytokines and Reagents. CHO cell-derived human rill2 was a gift from Dr. S. Wolf (Genetics Institute, Boston, MA); rlL-l~ (3.8 x 107 U/ml) was provided by the Division of Cancer Treatment (National Cancer Institute, Bethesda, MD); rlI~2 (107 U/mg) by Dr. T. Taguchi (Osaka University, Osaka, Japan); CHO cell-derived rlL-10 (1.5 x 107 U/mg) and rlL-D by Dr (41) . RIAs for human IFN-3' and human TNF-a were performed as described (42, 43) with mAbs B133.1/B133.5 and B154.9/B154.7, respectively. IL-12 p40 was measured in cell-free supernatants by ILIA as described (2) by use of the mAb pair Cll.79/C8.6. ILIA for IL-I~ was performed with mAbs F18 609/F18 206 (41) . ELISA for human IL-10 was purchased from Biosource International (Camarillo, CA).
quantitation of Biologically Active 11_, 12 Heterodimer by Antibody Capture Bioassay. The biological activity of IL-12 was determined by use of the capture bioassay previously described (3) . Briefly, the anti-IL-12 p40 antibody Cll.5 (2) was absorbed (15/xg/ml, 100 #l/well, in 0.1 M carbonate buffer, pH 9.5) for i>24 h at 4~ to bacteriological 96-well plates (Flow Laboratories, Inc., Rockville, MD). Plates were washed three times with PBS, and PBS/FCS 5% was added (200/zl, 1 h, 37~
After three washes, dilutions of rlIA2 standard or supernatant fluids to be tested were added (100/~l/well, for 3 h, at room temperature), plates were again washed (five times) and PHA blasts (5 x 10S/well) together with 100 U/ml of rlL-2 were added to the plates. After an 18-h incubation (37~ 5% CO2), supernatants were collected and tested for IFN-3, production by ILIA. The assay detects i>1 pg/ml of biologically active IL-12, is specific for Ib12, and, at least in the concentration range used in these experiments, is not affected by the presence of an excess of free p40 chains.
CellLines and PBMC Preparation. Peripheral blood obtained from healthy donors was anticoagulated with heparin. PBMC were separated on Ficoll-Hypaque (Lymphoprep; Nyegaard Co., Oslo, Norway) density gradient. When monocytes were used, they were obtained after adherence of the PBMC to plastic flasks by scraping the flasks with a rubber policeman after carefully rinsing out nonadherent cells with three washes with PBS. PHA blasts (>98% activated T cells) were obtained after 3-d culture of PBL in the presence of 1% PHA-M (44, 45) . The human EBV-transformed B lymphoblastoid cell line RPMI-8866 and the monocytic leukemia cell line THP-1 were grown in RPMI-1640 medium (Flow Laboratories, Inc.,) supplemented with 10% (20% for THP-1) heatinactivated FCS (Irvine Scientific, Santa Ana, CA). All tissue culture media and supplements were endotoxin flee. Cultures were performed in 96-well round-bottomed plates (Flow Laboratories, Inc.) with 106 cells/well. Cytokines to be tested were added at the onset of culture and kept in culture for 20 h before addition of the stimuli; supernatants were harvested after 18 h; IL-12 p40, TNFor, IL-1B, or II.,10 release was determined by use of specific RIAs, and IL-12 p70, by antibody capture bioassay. In some experiments, neutralizing anti-IL-4 mAb (25D2), anti-IL-10 mAb (19F1), at a concentration of 10/zg/ml each, were added to PBMC at different times during the culture assays before harvesting the supernatants for the specific RIAs.
Northern Blot Hybridization. Northern blots were performed as described (46) . Briefly, total RNA was extracted from induced and uninduced PBMC by the guanidine isothiocyanate method. Equal amounts of RNA (15 /zg/lane) were fractionated in a 1% agarose-formaldehyde gel. Gene expression was detected by sequential hybridization of nylon membranes (Schleicher & Schuell, Inc., Keene, NH) with 32p-cDNA probes for IL-12 p40, TNF-o~, IL-1/~/, and glyceraldehyde phosphate dehydrogenase (GAPD). Filters were exposed to film (X-Omat AR; Eastman Kodak Co., Rochester, NY) between double intensifying screens (DuPont Co., Wilmington, DE).
RNase Protection Assay. The entire coding region of p35 IL12 was amplified by PCR and subcloned into the pCRT~II vector, according to the suggestions of the manufacturer (Invitrogen Co., San Diego, CA). The vector was linearized with appropriate restriction enzymes and transcribed by use of [32p]UTP (NEN DuPont Co., Wilmington, DE) and a riboprobe kit (Promega Biotec, Madison, WI) into a complementary RNA (antisense) riboprobe containing a region of 240 bp complementary to the p35 IL-12 chain sequence. RNA samples (20/~g in 20/~1) were hybridized in solution with an excess of riboprobes (8-10 x 104 cpm, sp act 109 cpm//~g, 90~ for 5 min, 42~ for >10 h). RNase solution (200 /~1) was added for 30 min at 37~ and the instructions of a ribonuclease protection assay kit (model RPA II; Ambion Inc., Austin, TX) were followed. Protected fragments were fractionated on 5% polyacrylamide/urea sequencing gels and detected by autoradiography.
Results

Effect of Concomitant Treatment with IL-4, ILIO, and 71~F-El on LPS-and S. aureus-induced Production of lL-12 and Other
Cytokines by PBMC. As previously reported (14, 30) , stimulation of human PBMC with LPS or S. aureus in the presence of Ib4 or IL-13 inhibited the production ofTNF-o~, IL-1B, and IL-10 (results not shown). Production of the free IL-12 p40 chain or the biologically active IL-12 p70 heterodimer by LPS-stimulated PBMC was also inhibited by both IL-4 and II,-13 present during the 18-h stimulation (Table 1) . Northern blotting analysis showed that LPS induced accumulation of transcripts for TNF-c~ (peak at 1 h), IL~ p40 (peak at 4-8 h), and IL-1B (peak at 1-8 h) in PBMC (Fig. 1) . Like the observed effect on cytokine secretion, the presence of IL-4 during stimulation profoundly inhibited expression of both the IL-12 p40 and TNF-ol transcripts. These results extend the previous report that IL~ and IL-13 inhibit the accumulation of ILo12 transcripts induced by LPS in the presence of anti-IL-10 (30). The accumulation of IL-1B transcripts was only minimally decreased by Ib4, in contrast with the Ib4-mediated inhibition of IL-1B secretion (30 and Fig. 1 ). Unlike IL-4 inhibition of LPS-induced IL-12 production, the inhibition by IL-4 or IL-13 of IL-12 p40 or p70 production induced by S. aureus stimulation was often less consistent and, in most experiments, minimal or absent (Table 1) . TGF-~/1 and IL-10 effectively inhibited IL-12 production induced by either LPS or S. aureus (Table 1) .
PBMC Priming for IL-12 and TNF-e~ Production by Pretreatment with IL-4 or IL-13.
Unlike the inhibitory effects exerted by IL-4 and IL-13 when present during stimulation, pretreatmerit of PBMC for 20 h with IL-4 or IL-13 induced a threeto fourfold enhancement in their ability to produce IL-12 p40 and p70 in response to either LPS or S. aureus, and an approximately twofold increase in the production of TNF-c~, whereas IL-I~ and IL-10 production in response to LPS was inhibited (Tables 1 and 2 ). The inhibitory effect of TGF-B1 or IL-10 on IL-12 p40 and p70 production induced by either S. aureus or LPS was observed when PBMC were either stimulated in the presence of TGF-~I or IL-10 or were pretreated for 20 h with the two cytokines (Table 1) .
Neutralizing anti-IL-4 antibodies suppressed the ability of IL-4 to prime PBMC for IL-12 p40 production in response to S. aureus (Fig. 2) , indicating that this priming effect was mediated by IL-4 and not by contaminants in the preparation. Similar results were obtained with enriched monocyte preparations (adherent PBMC) instead of total PBMC (Table  3 and results not shown). Pretreatment of the macrophagelike cell line THP-1 with IL-4 also increased the production of IL-12 p40 in response to LPS and, to a lesser extent, S. aureus; however, ILo4 neither enhanced nor inhibited the constitutive or TPA-induced production of II,-12 p40 from the EBV-transformed B lymphoblastoid cell line RPMI-8866 (Table 3) .
Northern blot analysis (Fig. 3) showed that, like the effect of IL-4 on cytokine secretion, IL-4 pretreatment enhanced severalfold the accumulation of IL-12 p40 and TNF-c~ mRNA induced by either LPS or S. aureus. Unlike IL-4, pretreatment with TGF-~I inhibited accumulation of the transcripts for the two cytokines. Accumulation of the IL-12 p35 mRNA, much less abundant than p40 mRNA, was analyzed by the RNase protection method. Ib12 p35 transcripts were induced by LPS or S. aureus with a kinetics similar to that of IL-12 p40 mR.NA (Fig. 3 and not shown), and this induced accumulation was also enhanced severalfold by pretreatment of the PBMC with IL-4.
Inhibition of ILIO Production Does Not Play a Major Role in the Priming Effect of lL-4 and IL13 on IL12
Production. Because monocytes produce ILol0, a potent inhibitor of IL-12 production (3) (Fig. 4) , and because IL-10 production is inhibited by IL-4 (30) ( Table 2) , we tested the possibility that the priming effect of IL-4 and IL-13 was mediated by their inhibition of IL-10 production. However, in the present experimental conditions, ILo4 and ILo13 induced only a partial inhibition of LPS-induced IL-10 production and had no demonstrable effect on S. aureus-induced production ( Table 2 ). Fur- Figure 1 . Effect of rlL-4 on the LPS-induced accumulation of IL-12 p40, TNF-~x, and IL-1/~ mRNA in human PBMC. Total RNA was extracted from PBMC incubated for the indicated times in tissue culture medium or in the presence of LPS (1/~g/ml) with or without 10 ng/ml of human rib4. Cells stimulated in the presence oflb4 were pretreated for 4 h with the same concentration of Ib4. The RNA (15/~g/lane) was then hybridized in a Northern blot with 32p-labeled IL-12 p40, TNF-cx, Ibl~, or GAPD cDNA probes. * IL-4 (10 ng/ml) or IL-13 (10 ng/ml) was added to PBMC cultures 20 h before or at the time of stimulation with S. aureus (1:10,000 wt/vol) or with LPS (1/xg/ml). Cell-free supernatant fluids were collected after 18 h of stimulation; IL-12 p40 was determined by RIA and I1.-12 p70 by antibodycapture bioassay. Results are mean _+ SE of n experiments.
thermore, anti-IL-10 antibodies enhanced production of IL-12 p40 from both untreated and IL-4-or IL-13-primed PBMC (Fig. 4) . Thus, although endogenous IL-10 has an inhibitory effect on IL-12 p40 production, inhibition of IL-10 production is unlikely to be an important mechanism in the IL-4/IL-13-mediated priming in light of the at least additive effect of IL-4/IL-13 priming with anti-IL-10. However, addition of exogenous IL-10 almost completely inhibited IL-121040 production by either untreated or IL-4/IL-13-primed PBMC (Fig. 4) .
Kinetics and Dose Dependence of the Priming Effect of lL4 and IL13 on 11,12 p40 Production.
The maximum priming effect (20-h pretreatment) of both IL-4 and Ib13 for production of IL-12 p40 from human PBMC was observed at concentrations of 1-10 ng/ml. No significant increase in IL-12 p40 production was observed with any doses of ILo4 or ILo13 between 1 pg/ml and 10 ng/ml added during the 18-h stimulation, and an inhibitory effect was observed with the highest doses of IL-4 and IL-13 present during the 18-h-stimulation with LPS, but not consistently with S. aureus (Fig. 5 ). An optimal priming effect was observed when PBMC were pretreated with IL-4 or IL-13 for at least 20-24 h (Fig. 5) . In longer-term cultures, the IL-4-mediated enhancement of 
Effect of 20-h Pretreatment with IL-4 or IL-13 on Cytokine Production by PBMC Stimulated with LPS or S. aureus
TNF-cr
IL-1B IL-10 Cytokine* Stimulus (n = 16) (n = 6) (n = 4) l,g/ml * IL-4 (10/~g/ml) or IL-13 (10 #g/ml) was added to PBMC cultures. After a 20-h incubation, cultures were stimulated with S. aureus (1:10,000 wt/vol) or LPS (1/xg/ml). Cell-free supernatant fluid was collected after an 18-h stimulation, and TNF-~x, IL-I~, and IL-10 were quantitated by immunoassays. ILesults are mean _+ SE of n experiments.
monocyte ability to produce IL-12 and TNF-ot was observed in up to 3 d of culture (not shown).
Discussion
The data presented here show that treatment of PBMC with IL-4 or IL-13 for />20 h primes them for production of IL12 and TNF-cz in response to S. aureus and LPS, whereas their ability to produce IL-1B or IL-10 in response to LPS is impaired. These data contrast with the well-described ability of IL4 and IL-13, at least when added at the beginning or a few hours before stimulation of monocytes/macrophages. to inhibit production of a large number of cytokines, with the sole exception of IL-1RA (14, 30) . However, the ability of IL4 in some experimental conditions to act as costimulus for production of G-CSF and M-CSF from human monocytes (36) and TNF-ot from mouse peritoneal macrophages (37, 38) has been reported. Thus, the regulation of activa- tion and cytokine production mediated by IL-4 or ILo13 in monocytes/macrophages appears to be much more complex than that observed with IL-10 or TGF-B, cytokines that usually function as deactivating agents for monocytes/macrophages. In addition, the ability of IL-4 and IL-13 to reduce production of I1.-12 and other cytokines when present during stimulation of PBMC appears to depend on the stimulus used.
In contrast to IL-10 and TGF-/~I, which consistently inhibited cytokine production induced by either LPS or S. aureus, IL-4 and IL-13 often failed to inhibit cytokine production in response to S. aureus and were always less potent in inhibiting S. aureus-induced cytokine production when compared with their inhibition of LPS-induced cytokine production. The inhibition of IL-12 and TNF-a production and, partially, of IL-1/~ production by IL-4 is reflected by a decrease in accumulation of their mP, NA in LPS-stimulated cells. Previous studies (31) have indicated that this effect of IL-4 may be mediated by both transcriptional and posttranscriptional mechanisms. Unlike the inhibitory effect of IL-4 and IL-13 when present together with the cytokine-inducing stimulus, preincubation of PBMC with II.-4 and II:13 for >120 h primed the cells for production of IL-12 and TNF-c~ in response to both S. aureus and LPS, resulting in a threeto fourfold increase of both mRNA accumulation and protein secretion. In the absence of a cytokine-inducing stimulus such as S. aureus or LPS, IL-4 did not have a direct stimulatory effect on the mRNA accumulation or production of either IL-12 or TNF-ot. The priming effect of IL-4 and IL-13 was demonstrable on the induction of both the p35 and p40 genes. However, the ratio between the transcripts was not changed by priming, and, like unprimed cells, the IL-4-or IL-13-primed PBMC secreted the IL-12 p40 chain in large excess over the biologically active IL-12 p70 heterodimer. These effects of II.-4 and IL-13 contrast with those of IFN-% which directly stimulate expression of the p35 gene and induce priming for IL-12 p70 production more effectively than for IL-12 p40 production in both monocytes (13) and neutrophils (46a).
The ability of IL-4 to prime PBMC for cytokine production was not due to contaminants present in the preparation, because identical results were obtained with recombinant IL-4 from three different sources (not shown), and the effect was completely blocked by neutralizing anti-IL-4 antibodies. The nearly identical results obtained with IL-4 and IL-13, two cytokines that share many biological actions, confirms the specificity of the priming effect. Because IL-4 and IL-13 inhibit phagocytic cell production of IL-10, a powerful inhibitor of IL-12 and TNF-o~ production, it was possible that the priming effect of IL-4 and IL-13 on the production of these two cytokines was due to inhibition of IL-IO production. However, our data do not support this hypothesis because (a) IL-4 and IL-13 prime PBMC for production of IL-12 and TNF-ot in response to S. aureus, whereas they have only limited ability to inhibit IL-IO production in response to this stimulus; and (b) neutralizing anti-Ibl0 antibodies enhance production of 1I.-12 in response to either LPS and S. aureus by abolishing the inhibitory effect of endogenous IL-10, and this effect is synergistic with IL-4 or IL-13 priming, indicating that the ability of IL-4-or IL-13-primed PBMC to produce IL-12 is still inhibited by endogenous IL-10. Thus, although the inhibition of IL-10 may play a minor role in the mechanisms of IL-4 or Ib13 priming, especially in the case of LPS stimulation, the major mechanism of the priming appears to be independent of inhibition of IL-10 production.
The ability of IL-4 and IL-13 to prime PBMC for 1I.-12 production is particularly surprising because IL-12 and IL-4 are known to play an antagonistic role in inducing development of Thl and Th2 immune response, respectively (47) . The equilibrium between IL-12 and IL-4 early during an immune response most likely determines whether the response is Thl or Th2 (48) . However, it is likely that several modulatory mechanisms and both positive and negative feedback mechanisms intervene in the fine regulation of the Thl/Th2 dichotomy. Ib4 acts not only by downmodulating costimulatory signals expressed or secreted by accessory cells, but also by preventing the responsiveness of T cells to IL-2 (49). The priming effect of IL-4 and IL-13 on IL-12 production by PBMC is almost completely suppressed by IL-IO, another cytokine prevalently produced by Th2 cells, suggesting that the priming effect of IL-4 on II.-12 production is not effective when a Th2 response predominates. Even in the presence of high concentrations of Ib12 during an immune response, factors such as TGF-3 may suppress Thl cell differentiation in response to 11-12 and favor Th2 cell differentiation (Scharton-Kersten, T., L. C. C. Afonso, M. Wysocka, G. Trinchieri, and P. Scott, manuscript submitted for publication). Other exceptions to the rule that II.-4 and IL-12 favor Th2 and Thl differentiation, respectively, include the findings that IL-12 enhanced IL-4 production by IL-4-primed human cord blood CD4 § cells (50) , and that IL-12 in vivo induced IL-10 production in the mouse (51) .
The ability of IL-4 and IL-13 to prime monocytes for IL-12 and TNF-ol production is likely reflected in enhanced accessory cell activity of these cells. We observed that IL-4-and IL-13-primed PBMC have an enhanced ability to act as APC for antigen-induced IFN-'y production by most human tetanus toxoid-specific CD4 + clones (results not shown). IL-12 production from APC plays an important role in antigeninduced IFN-y production and, to some extent, in proliferation of CD4 § clones (4) . Thus, it is likely that the enhanced production of IL-12 is important for the enhanced APC activity of IL-4-and IL-13-primed cells, although other effects of IL-4, in particular the enhanced expression of MHC class II and other costimulatory factors such as TNF-c~, may play a role (52, 53) . The exact mechanism of the enhanced APC activity of IL-4-and IL-13-primed PBMC remains to be characterized. We have also observed that IL-4 and 11-13 treatment of monocytes enhances their ability to mediate TNF-ot-dependent cytotoxicity of the WEHI-164 cell line (results not shown), contrasting with the ability of IL-4 to inhibit antibodydependent cell-mediated cytotoxicity, due to inhibition of expression of Fc receptor on monocytes/macrophages (14, 37) . Not only does short-term treatment of PBMC with IL-4 or IL-13 enhances their APC function and ability to support antigen-dependent IFN-'y production, but long-term cultures of monocytes in the presence of GM-CSF and Ib4 give rise to cells with dendritic-like phenotype, which are very powerful APC (22, 23) and extremely effective producers of IL-12 (Kubin, M., and G. Trinchieri, unpublished results). These data suggest that IL-4 and IL-13, primary products of Th2 cells, might play a role in the differentiation and activation of APC, which, in the absence of other regulatory mechanisms, produce large amounts of IL-12 and may favor Thl cell development. The role of this activity of IL-4 or IL-13 in the complex regulatory interactions of the immune response remains to be clarified.
